Literature DB >> 7491048

Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity.

B J Cummings1, C W Cotman.   

Abstract

The protein beta-amyloid is said to be central to the disease process of Alzheimer's disease (AD). Several groups have developed transgenic models that overexpress the amyloid precursor protein or beta-amyloid and then develop AD-like neuropathology. Another report suggests that beta-amyloid accumulation in old dogs correlates with cognitive impairment. However, many other researchers argue that beta-amyloid deposition in senile plaques is a secondary event because plaque numbers in man do not correlate well with cognition. We set out to analyse this conumdrum in man. We selected 16 mild to severely demented AD cases on the basis of mini-mental state exam scores (MMSE; n = 16). We also included 4 controls who represented the upper range of cognitive ability. We used a computer-based image analysis of cross-sectional area of the brain occupied by beta-amyloid immunopositive deposition. We used this technique in preference to conventional methods of manual plaque counts and found a strong relation between beta-amyloid load in entorhinal cortex and cognition measured on various scales (r = -0.93 versus the Blessed IMC). Our study suggests that the size of cortical area affected by beta-amyloid deposition is an important factor in the clinical manifestation of dementia, and lends support to the possibility that beta-amyloid is central to the aetiology of AD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491048     DOI: 10.1016/s0140-6736(95)92053-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  61 in total

Review 1.  Protein aggregates and dementia: is there a common toxicity?

Authors:  S Lovestone; D M McLoughlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

2.  Pregnancy-related changes in connections from the cervix to forebrain and hypothalamus in mice.

Authors:  Steven M Yellon; Lauren A Grisham; Genevieve M Rambau; Thomas J Lechuga; Michael A Kirby
Journal:  Reproduction       Date:  2010-05-07       Impact factor: 3.906

3.  The Effects of Astilbin on Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Dongmei Wang; Sanqiang Li; Jing Chen; Ling Liu; Xiaoying Zhu
Journal:  Cell Mol Neurobiol       Date:  2016-07-19       Impact factor: 5.046

4.  Neuroprotection in Alzheimer's disease - new strategies for treatment.

Authors:  A Nordberg
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

6.  The fallacy of amyloid and cognition in Alzheimer's disease.

Authors:  Hyoung-gon Lee; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

7.  Cryogenic solid state NMR studies of fibrils of the Alzheimer's disease amyloid-β peptide: perspectives for DNP.

Authors:  Juan-Miguel Lopez del Amo; Dennis Schneider; Antoine Loquet; Adam Lange; Bernd Reif
Journal:  J Biomol NMR       Date:  2013-06-22       Impact factor: 2.835

8.  Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.

Authors:  D Wu; J Yang; W M Pardridge
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

9.  The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain.

Authors:  Jessica M McDonald; Nigel J Cairns; Lisa Taylor-Reinwald; David Holtzman; Dominic M Walsh
Journal:  Brain Res       Date:  2012-02-24       Impact factor: 3.252

10.  Retrograde tracing of spinal cord connections to the cervix with pregnancy in mice.

Authors:  Michael A Kirby; Mary M Groves; Steven M Yellon
Journal:  Reproduction       Date:  2009-12-04       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.